Northera approved for rare blood pressure condition

(HealthDay)—Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Neurogenic orthostatic hypotension (NOH) is most often associated with Parkinson's disease and other . Symptoms may include dizziness, lightheadedness, blurred vision, fatigue and fainting, the FDA said in a news release.

Granted accelerated approval to treat a rare condition, the drug will have a boxed label warning that it could cause an unhealthy rise in while a person is lying down. This potential side effect could lead to a stroke, the agency said, warning that Northera users should be monitored carefully.

Other less serious side effects could include headache, dizziness, nausea, and fatigue, the FDA said.

Northera is produced by Chelsea Therapeutics, based in Charlotte, N.C.

More information: The FDA has more about this approval.

Related Stories

Vimizim approved for rare childhood disorder

date Feb 17, 2014

(HealthDay)—Vimizim (elosulfase alfa) has been approved by the U.S. Food and Drug Administration to treat a rare childhood disorder called Mucopolysaccharidosis Type IVA, also known as Morquio A syndrome.

Iclusig approved for rare leukemias

date Dec 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Adempas approved to treat pulmonary hypertension

date Oct 09, 2013

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

Opsumit approved for pulmonary arterial hypertension

date Oct 23, 2013

(HealthDay)—Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.

Recommended for you

Japan's Takeda offers $2.2 bn to settle US drug lawsuits

date 20 hours ago

Japan's top drugmaker Takeda Pharmaceutical has offered $2.2 billion to settle US claims linked to its diabetes drug Actos, in what would be one of the biggest US payouts over patient lawsuits, a report said Wednesday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.